Posted by SLS on September 12, 2009, at 7:06:13
In reply to Re: The Final Pathway To The Dopaminergic Pot Of G, posted by Brainbeard on September 12, 2009, at 6:45:14
> Buspirone only temporarily decreases serotonin levels; they return back to normal within a couple of hours. So that probably couldn't provide a steady solution if your analysis is right.
>
> Remeron appears to be very sedating to most, not to mention its weight gain. I feel that sedation is likely to ruin the benefits of 5HT2A/C-antagonism.
>
> Cyproheptadine is an interesting drug, but also very antihistaminergic=sedative. Seems like a bit of a horse med, as we say in Holland.
>
> Your best bet may be the Prozac + buspirone. Personally, I do feel that stimulating drugs might help your symptoms. They can at least provide motivation and initiative, and perhaps make you happier as well.
>
> Unfortunately, stimulating meds usually have an anxiogenic effect on me. I sometimes feel biochemically stuck between lust for life + anxiety or lack of anxiety + apathy. I know I'm not the only one.
>
> It's too bad that pure 5HT2A/C-antagonists haven't found their way onto the market. It seems that they didn't do too well as antidepressants in the trials.It is unfortunate that the manner in which drugs are developed and brought to market currently provides no incentive to produce drugs that are active only as adjuncts to other drugs. A case in point would be gepirone, a 5-HT1a partial agonist. By itself, it did not seem to be robust as an antidepressant, but it would probably make a good augmentor for one. Another deficit is that compounds that have had their patents expire are not developed further to be marketed. An example of this would be ritanserin. It is a potent and selective antagonist of 5-HT2 receptors. Personally, I would like to have seen clorgyline brought to market as well. It is a MAOI that is specific for MAO-A.
- Scott
poster:SLS
thread:904542
URL: http://www.dr-bob.org/babble/neuro/20090701/msgs/916626.html